IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 278 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,937,784 | -34.2% | 2,843,469 | +1.8% | 0.01% | -31.6% |
| Q2 2023 | $19,670,633 | +19.4% | 2,794,124 | +3.6% | 0.02% | +11.8% |
| Q1 2023 | $16,477,705 | -3.3% | 2,696,842 | +1.2% | 0.02% | -5.6% |
| Q4 2022 | $17,033,056 | -31.9% | 2,665,580 | +2.1% | 0.02% | -35.7% |
| Q3 2022 | $25,000,000 | -14.2% | 2,609,705 | -1.1% | 0.03% | -6.7% |
| Q2 2022 | $29,127,000 | -30.0% | 2,638,302 | +5.6% | 0.03% | -16.7% |
| Q1 2022 | $41,584,000 | -10.6% | 2,497,533 | +2.5% | 0.04% | +44.0% |
| Q4 2021 | $46,519,000 | -21.9% | 2,436,816 | +0.9% | 0.02% | -24.2% |
| Q3 2021 | $59,569,000 | -5.1% | 2,415,613 | +0.1% | 0.03% | 0.0% |
| Q2 2021 | $62,767,000 | -17.2% | 2,412,203 | +0.7% | 0.03% | -15.4% |
| Q1 2021 | $75,809,000 | +6154.9% | 2,394,489 | +9067.3% | 0.04% | +3800.0% |
| Q4 2020 | $1,212,000 | -34.0% | 26,120 | -53.1% | 0.00% | 0.0% |
| Q3 2020 | $1,835,000 | -14.5% | 55,732 | -28.8% | 0.00% | -50.0% |
| Q2 2020 | $2,147,000 | +841.7% | 78,226 | +925.5% | 0.00% | – |
| Q1 2020 | $228,000 | -99.4% | 7,628 | -99.5% | 0.00% | -100.0% |
| Q4 2019 | $39,458,000 | +42.1% | 1,425,508 | -6.6% | 0.03% | +26.1% |
| Q3 2019 | $27,772,000 | -27.9% | 1,525,922 | -2.8% | 0.02% | -32.4% |
| Q2 2019 | $38,505,000 | +114.2% | 1,570,306 | -16.9% | 0.03% | +112.5% |
| Q1 2019 | $17,977,000 | +7.5% | 1,890,294 | +0.0% | 0.02% | -5.9% |
| Q4 2018 | $16,725,000 | -4.7% | 1,889,873 | +21.1% | 0.02% | +6.2% |
| Q3 2018 | $17,559,000 | +33.0% | 1,560,825 | +51.3% | 0.02% | +23.1% |
| Q2 2018 | $13,200,000 | -46.2% | 1,031,314 | -29.0% | 0.01% | -43.5% |
| Q1 2018 | $24,532,000 | +179.9% | 1,451,560 | +32.5% | 0.02% | +187.5% |
| Q4 2017 | $8,763,000 | +1434.7% | 1,095,428 | +1386.5% | 0.01% | +700.0% |
| Q3 2017 | $571,000 | +191.3% | 73,694 | +177.6% | 0.00% | – |
| Q2 2017 | $196,000 | – | 26,551 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |